Nanobiotix Reports Phase 1 Melanoma Data, ORR 41.7%

The company reported final data in anti-PD-1-resistant primary cutaneous melanoma, including median PFS of 6.9 months and median OS of 17.8 months among 24 patients. Responses occurred in injected and non-injected lesions, with no new safety signals.